{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:33:19Z","timestamp":1766503999760},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Cisplatin is the principal chemotherapeutic agent and also tremendously increases the survival for pediatric patients with neuroblastoma or hepatoblastoma. With the extended overall survival period, clinical medical workers and parents gradually attach more attention to the late effect of chemotherapy of these children. The purpose of this study is to analyze the incidence and risk factors of cisplatin-based hearing loss. We retrospectively collected the archives of cisplatin-based chemotherapy and audiometric evaluation from 2005 through 2017 at Xinhua Hospital. From 384 patients treated with cisplatin, full data of 59 patients were available, and 14 cases (23.7%) were identified as significant hearing loss. The median time from usage of platinum compounds to the most recent audio test was 406 days. Cumulative and single maximum cisplatin dose was 622.6\u00b1283.2 and 137.6\u00b151.6\u2009mg\/m<jats:sup>2<\/jats:sup>\/cycle, respectively. Accumulated cisplatin dose (95% confidence interval, 1.001-1.006; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.012) and single maximum cisplatin dose (95% confidence interval, 1.000-1.029; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.049) were independently important predictors for moderate to severe hearing loss in children treated with cisplatin. Cisplatin can cause ototoxicity which profoundly handicap language development and social communication for children. Regular audiological management and long-term follow-up are strongly recommended for this vulnerable group.<\/jats:p>","DOI":"10.1097\/mph.0000000000001282","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T20:02:44Z","timestamp":1533758564000},"page":"e97-e100","source":"Crossref","is-referenced-by-count":27,"title":["Cisplatin-induced Ototoxicity in Children With Solid Tumor"],"prefix":"10.1097","volume":"41","author":[{"given":"Meng","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/14992027.2010.485595","article-title":"Long term hearing degeneration after platinum-based chemotherapy in childhood","volume":"49","author":"Einarsson","year":"2010","journal-title":"Int J Audiol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MPH.0b013e3181cb8593","article-title":"Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens","volume":"32","author":"Kolinsky","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","article-title":"Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss","volume":"26","author":"Bertolini","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e31815d1d83","article-title":"Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens","volume":"30","author":"Dean","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/13816810.2015.1137325","article-title":"Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma","volume":"38","author":"Geurtsen","year":"2017","journal-title":"Ophthalmic Genet"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00787-015-0697-1","article-title":"Emotional and behavioural difficulties in children and adolescents with hearing impairment: a systematic review and meta-analysis","volume":"24","author":"Stevenson","year":"2015","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2016.02.051","article-title":"Multidisciplinary effort in treating children with hepatoblastoma in China","volume":"375","author":"Yuan","year":"2016","journal-title":"Cancer Lett"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/pbc.23275","article-title":"Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach","volume":"58","author":"Orgel","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2009.24.4228","article-title":"Practical grading system for evaluating cisplatin ototoxicity in children","volume":"28","author":"Chang","year":"2010","journal-title":"J Clin Oncol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.ejca.2003.08.009","article-title":"Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose","volume":"40","author":"Li","year":"2004","journal-title":"Eur J Cancer"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3892\/ol.2012.997","article-title":"Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients","volume":"5","author":"Nitz","year":"2013","journal-title":"Oncol Lett"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cncr.22004","article-title":"Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma","volume":"107","author":"Kushner","year":"2006","journal-title":"Cancer"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/pbc.21898","article-title":"Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma","volume":"52","author":"Jehanne","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1542\/peds.2007-0178","article-title":"Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children\u2019s Oncology Group","volume":"120","author":"Gurney","year":"2007","journal-title":"Pediatrics"},{"key":"R15-20230918","first-page":"149","article-title":"Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin","volume":"214","author":"Sivaprakasam","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1002\/cncr.24668","article-title":"Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears","volume":"115","author":"Sullivan","year":"2009","journal-title":"Cancer"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/pbc.25123","article-title":"Incidence of platinum-induced ototoxicity in pediatric patients in Quebec","volume":"61","author":"Peleva","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/pbc.24138","article-title":"Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients","volume":"59","author":"Yancey","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-2002-33179","article-title":"The incidence of hearing impairment after successful treatment of neuroblastoma","volume":"214","author":"Simon","year":"2002","journal-title":"Klin Padiatr"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","article-title":"Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer","volume":"34","author":"Frisina","year":"2016","journal-title":"J Clin Oncol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1542\/peds.2009-1597","article-title":"Auditory late effects of childhood cancer therapy: a report from the Children\u2019s Oncology Group","volume":"125","author":"Grewal","year":"2010","journal-title":"Pediatrics"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2013.6296","article-title":"Clinical ascertainment of health outcomes among adults treated for childhood cancer","volume":"309","author":"Hudson","year":"2013","journal-title":"JAMA"},{"key":"R24-20230918","first-page":"158","article-title":"Dose-dependent inner ear changes after i.v. administration of cisplatin","volume":"20","author":"Laurell","year":"1991","journal-title":"J Otolaryngol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000099020","article-title":"Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig","volume":"12","author":"Laurell","year":"2007","journal-title":"Audiol Neurootol"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tips.2013.05.006","article-title":"Understanding platinum-induced ototoxicity","volume":"34","author":"Langer","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"R27-20230918","first-page":"1","article-title":"Ototoxicity monitoring in children treated with platinum chemotherapy","volume":"24","author":"Brooks","year":"2017","journal-title":"Int J Audiol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201903000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:53:58Z","timestamp":1695012838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201903000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001282","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}